PMAIP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL19615054	0.78	13/20
SCHEMBL19635376	0.70	13/20
SCHEMBL19635561	0.70	13/20
SCHEMBL19635648	0.70	13/20
SCHEMBL19615094	0.69	13/20
SCHEMBL19635588	0.61	13/20
SCHEMBL19634931	0.60	13/20
SCHEMBL19634929	0.60	13/20
SCHEMBL19634964	0.55	13/20
SCHEMBL19635132	0.55	13/20
SCHEMBL19615852	0.82	12/20
SCHEMBL19615128	0.72	12/20
SCHEMBL19615112	0.71	12/20
SCHEMBL19615433	0.65	12/20
SCHEMBL19635128	0.61	12/20
SCHEMBL19615086	0.59	12/20
SCHEMBL19635343	0.59	12/20
SCHEMBL19635399	0.59	12/20
SCHEMBL19635133	0.52	12/20
SCHEMBL19615105	0.75	11/20

Clinical trials — most relevant to PMAIP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Ibuprofen, Paracetamol and Their Combination on Radical Oxygen Species (ROS) Production	PHASE4	COMPLETED
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly	PHASE4	COMPLETED
Centocor Microarray Study of Patients	PHASE4	COMPLETED
Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone	PHASE3	UNKNOWN
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	PHASE1/PHASE2	RECRUITING
Biologic Correlative Taxotere/AC	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
FITMI - First In Treating Male Infertility	PHASE2	ACTIVE_NOT_RECRUITING
Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer	PHASE1	COMPLETED
Effects of p38 MAPK Inhibitor POLB 001 on in Vivo LPS Challenge Responses	PHASE1	COMPLETED
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma	PHASE1	COMPLETED
Phase I Study of APX005M in Pediatric Central Nervous System Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Epigenetic Reprogramming in Relapse/Refractory AML	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients	PHASE1	UNKNOWN
An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?	nan	UNKNOWN
Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor	nan	COMPLETED
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED
Impact of Intermittent Hypoxia on Neutrophil Extracellular Traps	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
Biomarkers and Disease Activity in Patients Treated With Teriflunomide (Aubagio)	nan	COMPLETED
Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients	nan	RECRUITING
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches	nan	UNKNOWN
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir	nan	WITHDRAWN
Novel Biomarkers in Inflammatory Bowel Disease	nan	COMPLETED
Immune Cell Response to Stimuli	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PMAIP1 binder may also engage these)

Protein	Name	Similarity
Q1PCT2	—	0.994	Q1PCT2 →
P08229	—	0.993	P08229 →
P14998	—	0.992	P14998 →
Q3L6L9	—	0.992	Q3L6L9 →
Q9M280	—	0.991	Q9M280 →
Q5R8D4	—	0.991	Q5R8D4 →
P68596	—	0.991	P68596 →
P0DOU0	—	0.991	P0DOU0 →
P68595	—	0.991	P68595 →
P0DOT9	—	0.991	P0DOT9 →
P61467	—	0.991	P61467 →
B8ELF9	—	0.991	B8ELF9 →
P03086	—	0.990	P03086 →
Q10926	—	0.990	Q10926 →
Q85FI2	—	0.990	Q85FI2 →
P38311	—	0.990	P38311 →
B9J2V0	—	0.990	B9J2V0 →
O62692	—	0.990	O62692 →
A2C4H7	—	0.990	A2C4H7 →
Q7MXZ3	—	0.990	Q7MXZ3 →
Q6JL78	—	0.990	Q6JL78 →
P0DON5	—	0.990	P0DON5 →
P69469	—	0.990	P69469 →
P07718	—	0.989	P07718 →
P03085	—	0.989	P03085 →
Q41898	—	0.989	Q41898 →
Q47U34	—	0.989	Q47U34 →
Q8NCQ3	—	0.989	Q8NCQ3 →
A2BYF5	—	0.989	A2BYF5 →
Q495D7	—	0.989	Q495D7 →